Skye Bioscience (SKYE) Q3 2024 earnings summary

Executive summary

• Focused on developing nimacimab, a peripherally restricted CB1 inhibitor, as a novel non-incretin therapy for obesity and metabolic diseases, with a strong emphasis on safety and efficacy.

• Transitioned to a metabolic health focus, launching the CBEYOND Phase 2 obesity trial for nimacimab, with strong enrollment and robust study design including monotherapy and combination arms.

• Preclinical data showed nimacimab induced up to 16% dose-dependent weight loss in a humanized mouse model, with significant fat loss and lean mass preservation and no neuropsychiatric adverse events.

• Completed two PIPE financings in January and March 2024, raising $83.6M net, and uplisted to NASDAQ in April 2024.

• Discontinued ocular program after Phase 2a trial failed to meet endpoints, reallocating resources to metabolic pipeline.

Financial highlights

• Research and development expenses rose to $4.9 million in Q3 2024 from $1.3 million in Q3 2023, mainly due to clinical and manufacturing costs for the phase 2 trial.

• General and administrative expenses increased to $4.6 million from $2.2 million year-over-year, driven by stock-based compensation and professional services.

• Net loss for Q3 2024 was $3.9 million, a significant improvement from $24.9 million in Q3 2023, primarily due to the prior year's $21.2 million asset acquisition expense.

• Cash and cash equivalents stood at $76.5 million as of September 30, 2024, including $9.1 million restricted cash; up from $1.3 million at year-end 2023.

• Recognized $1 million in interest income and $4.6 million from derecognition of liabilities and legal recoveries.

Outlook and guidance

• Cash runway expected to fund operations and the phase 2 trial through Q3 2027, extending one quarter beyond previous estimates.

• Interim Phase 2 data for nimacimab in obesity targeted for Q2 2025, with topline data expected in Q4 2025.

• Burn rate is approximately $6 million per quarter, projected to rise to $9 million per quarter in 2025.

• No revenue expected until regulatory approval and commercialization of nimacimab or future candidates.